Lupus anticoagulant: interference with in vivo prostaglandin production and with platelet sensitivity to prostacyclin.
The hypothesis has been made that inhibition of prostacyclin (PG12) production may play a role in the pathogenesis of thrombosis in patients with the lupus anticoagulant (LA), but so far no evidence of reduced PG12 levels in vivo has been produced. We have tested the plasma levels of PG12 and thromboxane A2 (TXA2) and the platelet sensitivity to PG12 in 14 patients with and without LA and in 14 healthy controls. No significant difference in the prostanoid basal levels was detected among the groups; however, in some patients PG12 increments seemed to parallel the clinical course of the disease. Platelet sensitivity to exogenous PG12 was significantly enhanced in the LA + patients and correlated with PG12 values. We suggest that in these subjects additional factors, other than reduced PG12, may predispose to thrombosis.
Schinco
P C
PC
Department of Medicine, University of Turin, Molinette Hospital, Italy.
Marranca
D
D
Bazzan
M
M
Borchiellini
A
A
Fantino
A
A
Garis
G
G
Melzi
E
E
Modena
V
V
Tamponi
G
G
Tavella
A M
AM
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D011464:Epoprostenol / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000502:physiology*; D008180:Lupus Erythematosus, Systemic / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D008947:Mixed Connective Tissue Disease / Q000378:metabolism / Q000503:physiopathology; D011453:Prostaglandins / Q000378:metabolism*; D012595:Scleroderma, Systemic / Q000378:metabolism / Q000503:physiopathology; D013928:Thromboxane A2 / Q000378:metabolism
D016682:Lupus Coagulation Inhibitor; D011453:Prostaglandins; D013928:Thromboxane A2; D011464:Epoprostenol